Wegovy Injection Site Reactions That Won't Go Away: When to Worry and What to Do

How Common Are Injection Site Reactions With Wegovy?

Injection site reactions are among the more frequently reported local side effects of subcutaneous semaglutide, though they occur far less often than nausea or other gastrointestinal effects. In the STEP 1 trial (N=1,961), injection site reactions occurred in 3.2% of participants receiving semaglutide 2.4 mg weekly compared with 2.8% on placebo, a small but real difference [1]. Reactions were predominantly mild and self-limiting. Pooled across the STEP program, the discontinuation rate attributed specifically to injection site reactions was below 0.2% [2].

The current Wegovy prescribing information lists erythema, pain, swelling, induration, and pruritus at the injection site among reported reactions and instructs patients to let the pen reach room temperature before injecting [3]. The label does not specify a firm timeline for when a reaction should be considered abnormal, which is the gap this article addresses.

FDA's Adverse Event Reporting System (FAERS) is a voluntary, unverified reporting database rather than a controlled study, but it does contain reports describing injection site nodules, localized fat tissue change, and induration lasting beyond the typical several-day window [4]. These reports cannot establish a rate or confirm causation, but they describe a recognizable pattern distinct from the transient soreness most patients experience.

Why Injection Site Reactions Happen

Two overlapping processes explain a subcutaneous injection site reaction: mechanical tissue disruption and a local immune response.

Semaglutide is delivered via a prefilled pen with a thin-gauge needle (29 to 31 gauge). Depositing drug solution into the subcutaneous fat layer causes brief mechanical irritation that typically resolves within days. A separate driver is the local tissue response to the injected formulation and the peptide itself, a mechanism discussed in general literature on subcutaneous drug injection site reactions [5].

Semaglutide's fatty acid side chain, which extends its half-life to about a week by binding circulating albumin, means the drug forms a temporary depot at the injection site before it disperses into systemic circulation. That protraction mechanism is well described in the pharmacology literature on long-acting GLP-1 derivatives [6]. Whether that depot triggers a localized immune infiltrate in some patients is biologically plausible but is not something the protraction-chemistry literature itself demonstrates; it is better supported by dermatology and allergy case reports discussed below, and remains an area where individual biopsy findings would be needed to confirm a mechanism in a specific patient.

Temperature may also play a role. The label recommends letting the pen reach room temperature before use, and general injection-technique literature associates injecting cold medication with more local discomfort and induration, though this has not been studied specifically for semaglutide [3].

Defining "Persistent": What Normal Resolution Looks Like vs. What Doesn't

A typical reaction follows a predictable arc: redness and mild swelling within minutes to hours, pain peaking around 6 to 12 hours, visible signs fading by 48 to 72 hours, and a normal-feeling site by day 5.

Persistent reactions break this pattern. Allergy literature on injection and vaccine site reactions distinguishes reactions by immunologic mechanism, and the distinction matters for management [7]:

Immediate reactions (Type I, IgE-mediated) appear within about 60 minutes as urticaria or a wheal-and-flare, sometimes with localized swelling. These are uncommon with semaglutide and usually resolve within 24 hours with antihistamines. If a reaction of this type recurs and worsens with each injection, it raises concern for true drug allergy and should be evaluated.

Delayed reactions (Type IV, T-cell-mediated) are the more likely explanation for a reaction that will not resolve. These appear 48 to 72 hours after injection and present as firm, sometimes itchy, indurated areas that can persist for weeks. Case reports of delayed hypersensitivity to GLP-1 receptor agonists presenting as persistent subcutaneous nodules exist in the endocrinology literature; the specific case series referenced in earlier drafts of this material could not be verified to a citable article and should be confirmed against a specific paper before it is presented to readers as established evidence [8].

Lipohypertrophy, a localized buildup of subcutaneous fat from repeated injection into the same area, is a third mechanism. It is well documented with insulin, where studies have found it common among patients who do not rotate sites adequately, though reported prevalence varies across studies and a precise figure should be checked against the specific source before publishing [9]. Whether the same process, and at what rate, applies to weekly semaglutide injections has not been directly studied, but repeated injection into an unrotated site is a reasonable risk factor to flag for any subcutaneous drug.

A Decision Framework for a Reaction That Won't Resolve

Not every persistent reaction calls for the same response. Organizing the decision around how long the reaction has lasted, rather than treating "still there" as one category, helps a patient or clinician decide what to do next.

Still present at 7 days. This exceeds typical resolution but can still reflect slow depot absorption, especially with a higher local fat layer or a cold-injected dose. What to do: warm compresses for 10 to 15 minutes twice daily, review injection technique and whether the pen was warmed to room temperature, and photograph the site for comparison. No dose change is usually needed at this point.

Still present at 14 days. Two full weeks is unlikely to be simple mechanical irritation. Consider delayed-type hypersensitivity (firm induration, with or without itching), early lipohypertrophy (a painless, rubbery area), or injection that landed in the dermis rather than the subcutaneous layer. What to do: get a clinical evaluation with visual inspection and palpation, mark the area to track whether it is expanding or shrinking, and review injection depth, angle, and site rotation with the prescriber.

Still present at 28 days. A month-old reaction needs active investigation rather than continued watchful waiting. Reasonable next steps include dermatology referral for possible biopsy of a persistent nodule, an allergy workup if reactions recur at more than one site, and a decision with the prescriber about continuing Wegovy as-is, adjusting the injection protocol, or switching agents.

The exception that changes this timeline: any sign of infection (expanding warmth, fever, drainage) or systemic allergy (hives away from the site, facial or throat swelling, trouble breathing) moves straight to urgent evaluation regardless of how many days have passed. See the red-flag list below.

In practice, clinicians who manage these reactions often find that technique review resolves a meaningful share of persistent cases before an allergy workup is needed, since injection depth, site rotation, and temperature are the most common fixable contributors. That is a general clinical pattern, not a specific published statistic, and it does not rule out true hypersensitivity in an individual patient.

Managing a Persistent Reaction

Start with the simplest interventions before escalating.

Temperature and technique. Let the Wegovy pen sit at room temperature for about 30 minutes before injecting, pinch the skin to ensure the needle reaches subcutaneous depth, and avoid a rushed injection. General injection-technique research has found that slower injection speed and controlled volume reduce perceived pain and local induration compared with a rapid bolus, though the specific magnitude reported in any one study should be confirmed before quoting an exact percentage to a patient [10].

Site rotation. Rotating consistently among the abdomen, anterior thigh, and posterior upper arm, and avoiding re-injection within about 2 inches of a recent site, is standard practice reflected in obesity-pharmacotherapy guidelines and in general subcutaneous-injection guidance [11]. A simple approach: divide the abdomen into quadrants and rotate through them weekly, skipping any quadrant with a palpable residual nodule.

Topical treatment. For a firm, itchy area consistent with a delayed hypersensitivity pattern, a mid-potency topical corticosteroid (such as triamcinolone 0.1% or betamethasone valerate 0.1%) applied twice daily for 5 to 7 days is a reasonable extrapolation from dermatologic management of other subcutaneous drug reactions, though this has not been studied specifically in Wegovy users and should be confirmed with a prescriber first [12]. Oral antihistamines may help itching but will not speed resolution of an indurated nodule.

Ice, then warmth. Ice wrapped in a cloth for about 10 minutes right after injection is a commonly recommended way to blunt initial inflammation. Starting the next day, warm compresses for about 15 minutes twice daily are commonly recommended to support drug depot absorption and local blood flow. The order matters more than the total time: ice first, warmth later.

When a Persistent Reaction Signals Something More Serious

Some patterns need medical attention rather than watchful waiting.

Expanding redness with warmth and fever can indicate cellulitis, a bacterial skin infection. Any skin puncture, including an injection, is a potential entry point for common skin bacteria [13]. Cellulitis needs antibiotics, not topical corticosteroids, and should not be managed at home.

Pus or a soft, fluctuant area suggests a possible abscess. This is uncommon with a thin-gauge prefilled pen but is not impossible, and FAERS contains reports describing it for injectable GLP-1 receptor agonists [4]. It needs in-person evaluation.

A spreading firm area with smaller satellite bumps around the original site raises concern for a granulomatous foreign-body-type reaction to the injected material. Dermatopathology literature describes granulomatous responses to injected material that can resemble other skin conditions on biopsy, which is one reason a persistent, spreading nodule may ultimately need a tissue sample to characterize [14].

Systemic symptoms with a local reaction, such as hives away from the injection site, swelling of the lips, tongue, or throat, trouble breathing, or lightheadedness, point toward a systemic allergic reaction and need emergency evaluation. The STEP trials excluded people with known semaglutide hypersensitivity, and postmarketing reports of severe allergic reactions exist in FDA's safety reporting system, which is one reason new or worsening systemic symptoms should not be waited out [3, 4].

If Reactions Persist Despite Optimizing Technique

For someone who has warmed the pen, rotated sites carefully, and still gets a reaction every dose, the next question is whether to change how the drug is delivered or switch agents.

Oral semaglutide (Rybelsus). Because it removes the injection entirely, oral semaglutide eliminates the local-reaction variable. A clinical trial of oral semaglutide 50 mg reported substantial mean weight loss at 68 weeks, in a range comparable to subcutaneous dosing, though the exact percentage should be checked against the published trial before it is quoted precisely [15]. The trade-off is a strict fasting requirement around dosing and a gastrointestinal side effect profile during titration that some patients find harder to tolerate than the injectable form.

Tirzepatide (Zepbound). Tirzepatide is a different molecule, with a different formulation and injection device. Injection site reactions still occur, reported in the SURMOUNT-1 trial at a rate broadly similar to what is seen with semaglutide, but the underlying chemistry and excipients differ [16]. A patient with a reaction pattern consistent with hypersensitivity to semaglutide specifically may or may not react the same way to tirzepatide; there is no guarantee either way, and this is a decision to make with a prescriber rather than a switch to try on one's own.

Consensus obesity-treatment guidance generally supports trying an alternative agent within the GLP-1/GIP class before concluding a patient cannot tolerate the class at all, when the problem is localized to the injection site rather than systemic [17]. In practice, this means a reaction confined to the skin, without systemic allergic symptoms, is usually a reason to troubleshoot technique and consider a switch rather than to stop treatment for obesity or type 2 diabetes altogether without discussing alternatives.

Documenting and Reporting a Persistent Reaction

For a reaction lasting beyond 14 days, photographing the site at the time of injection, and again at day 3, day 7, and day 14, gives a clinician something concrete to evaluate. Measuring redness in centimeters and noting texture (soft, firm, or fluctuant) and associated symptoms (pain, itching, warmth) makes the evaluation faster and more useful.

Patients and clinicians can report an unusual or persistent injection site reaction to FDA MedWatch, which feeds the FAERS database used for postmarketing safety signal detection [4]. If the product packaging or pharmacy materials include a manufacturer safety-reporting contact, that is worth using as well; this article does not assume specific contact details beyond what is printed with the product, since those can change.